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Fascin, an actin-bundling protein involved in cell motility, has been shown to be upregulated in several types of carcinomas. In this
study, we investigated the expression of fascin in 228 advanced colonic adenocarcinoma patients with a long follow-up. Fascin
expression was compared with several clinicopathologic parameters and survival. Overall, fascin immunoreactivity was detected in
162 (71%) tumours with a prevalence for right-sided tumours (Po0.001). Fascin correlated significantly with sex, tumour grade and
stage, mucinous differentiation, number of metastatic lymph nodes, extranodal tumour extension, and the occurrence of distant
metastases. Patients with fascin-expressing tumours experienced a shorter disease-free and overall survival in comparison with those
with negative tumours, and fascin immunoreactivity emerged as an independent prognostic factor in the multivariate analysis.
Moreover, patients with the same tumour stages could be stratified in different risk categories for relapse and progression according
to fascin expression. Our findings suggest that fascin is a useful prognostic marker for colonic adenocarcinomas.
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Colorectal cancer is among the most commonly diagnosed
malignancies, ranking fourth in frequency in men and third in
women (Parkin et al, 2005). Although the prognosis has slightly
improved in the last few years (survival estimates at 5 years are now
65% in North America and 54% in Western Europe) (Parkin et al,
2005), colonic cancer is still a major cause of death worldwide.
The recent introduction of new chemotherapeutic combinations
of adjuvant chemotherapy has improved the disease-free survival
(DFS) of stage III patients (Gramont, 2005). Nevertheless, a
consistent fraction of patients with locally advanced colonic
carcinoma will relapse (Obrand and Gordon, 1997; Gramont,
2005), mostly within the first 3 years (Sadahiro et al, 2003). One of
the reasons accounting for this failure may be the difficulty in
stratifying patient groups with locally advanced disease in different
risk categories. The issue of prognostic heterogeneity for patients
with stage III colorectal cancer (Merkel et al, 2001) has, in part,
been addressed by the last TNM edition, where colonic carcinoma
patients are substaged according to the depth of the intestinal wall
invasion and the number of lymph nodes involved (Greene et al,
2002). In this scenario, a large number of biomolecular markers
have been suggested as new prognostic factors in locally advanced
colonic carcinomas, but there are insufficient data or a poor
clinical translation for most of them (Duffy et al, 2003; Funaioli
et al, 2006).
The interaction among cancer cells, extracellular matrix
proteins, and endothelial cells plays a major role in local invasion
and distant metastases (Aznavoorian et al, 1993; Alessandro et al,
1996; Liotta and Kohn, 2001). Invasive tumour cells are often
characterised by changes in cell shape with the appearance of
membrane protrusions, loss of anchorage dependency, and loss
of cell–cell adhesion and junctional communications. Many of
these changes are related to re-arrangements of the cytoskeletal
microfilaments because of the action of several types of actin
cross-linking proteins (Maekawa et al, 1988; Tilney et al, 1998).
Among these molecules, fascins are involved in the organisation
of two major forms of actin-based structures that include cortical
cell protrusions such as filopodia, spikes, lamellipodial ribs,
dendrites and microvilli, and cytoplasmic microfilament bundles
(Kureishy et al, 2002). Fascin, which is expressed in normal
mesenchymal, endothelial, dendritic, and neuronal cells but not in
normal epithelia (Kureishy et al, 2002) is important in cell–cell
interactions and adhesion (Adams et al, 2001), both interacting
with specific tight (Wong et al, 1999) and adherens junctions (Tao
et al, 1996) and intervening in focal adhesions via b1-integrin
(Jawhari et al, 2003). Moreover, the protein promotes cell
locomotion (Yamashiro et al, 1998) and participates in the
mechanical organisation of stress fibres (Adams, 1997). A definite
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soverexpression of fascin has been reported in carcinomas of
different organs, including oesophagus (Hashimoto et al, 2005a;
Xie et al, 2005; Zhang et al, 2006), stomach (Hashimoto et al,
2004), colon (Jawhari et al, 2003; Hashimoto et al, 2006), pancreas
(Maitra et al, 2002), breast (Grothey et al, 2000; Yoder et al, 2005),
skin (Goncharuk et al, 2002), lung (Pelosi et al, 2003a,b; Choi et al,
2006), urinary bladder (Tong et al, 2005), and ovary (Hu et al,
2000) and the protein has been recently proposed as a novel
biomarker for aggressive tumour behaviour (Hashimoto et al,
2005b, 2006; Zhang et al, 2006). In colonic adenocarcinoma cell
lines, fascin overexpression correlates with an increase in the
formation of dynamic cell protrusions, proliferation, and inva-
siveness (Jawhari et al, 2003). Besides, more recently, in CRC,
fascin overexpression has been shown to correlate with proximal
colon tumour location and shorter patients’ survival (Hashimoto
et al, 2006).
In this study, we investigated the prevalence and clinicopatho-
logical implications, including survival, of fascin immunoreactivity
in either primary tumours or lymph node metastases of 228
patients with stage III–IV colonic adenocarcinoma. Our results
support the view that fascin correlates with a tumour cell invasive
phenotype, emerging as an independent predictor of reduced
survival.
MATERIALS AND METHODS
Patients and tumours
Three hundred consecutive patients with stage III and IV (6th
TNM classification of malignant tumours) advanced colorectal
adenocarcinoma (231 colonic and 69 rectal) were identified and
surgically treated at the European Institute of Oncology and at
the University Hospital of Verona between 1988 and 1999. As this
study was aimed at assessing the role of fascin in tumour
progression of advanced colonic adenocarcinoma, we also
included stage IV patients in the survival analysis, whereas the
earlier stages of disease were not taken into account. Other
inclusion criteria were no neo-adjuvant treatment and age p85
years (three patients aged 87, 88, and 92 years were excluded). All
the data were retrieved from the original clinical charts, databases
of the participating institutions, through direct interviews with
surviving patients or their family members, family physicians, or
the death registry office. The data that was analysed included the
date of birth, date of surgery, date of last follow-up/death, date
of local recurrence, date of first metastatic spreading, site of
metastatic spreading (classified as local recurrence, hepatic,
abdominal extra-hepatic, and distant), and the anatomical location
of the neoplasm (classified as right, transverse, and left colon).
Information on overall survival (OS) was available for all
patients, with 141 of them (61.8%) dying from their disease. The
mean survival period was 54.2 months (standard deviation 43.1;
range 0–106 months). Recurrent disease information was asses-
sable in 220 (96%) patients, with a mean time to event of 39.0
months (standard deviation 38.6; range 0–170 months). Informa-
tion on adjuvant therapy was available for 205 patients (90%) (116
treated and 89 not treated). Because of the different biological,
clinicopathologic, and therapeutic implications of rectal cancer
(with particular reference to the role of additional therapies in the
management of these patients) (Rodel and Sauer, 2004), rectal
adenocarcinomas were recorded for the prevalence of fascin
immunoreactivity but then excluded from any further clinico-
pathologic and survival analysis.
The paraffin blocks of all cases were retrieved and the original
haematoxylin and eosin-stained sections reviewed for confirma-
tion of pT3 or pT4 status, histologic tumour grade (categorised
with a three-tier grading system using the extent of gland
formation and microtubular structures as the primary grade
criteria (Grinnell, 1939; Jass et al, 1986), tumour type, occurrence
of vascular (classified as intramural and extramural venous vessels
or lymphatic channels), and perineural invasion; tumour growth
patterns (expansive or infiltrative margins); number of metastatic
lymph nodes, and the occurrence of extracapsular lymph node
involvement.
Immunocytochemistry and evaluation of data
Formalin-fixed and paraffin-embedded tissue samples obtained
at surgery were investigated. Tumours up to 2cm in size were
entirely embedded and immunostained. Ten samples of normal
colonic wall from patients with nonmalignant intestinal diseases
and peritumoural colonic tissue from the same cohort of patients
investigated provided the control groups for noncarcinoma and
carcinoma patients, respectively.
Fascin was immunolocalised on 4-mm-thin tissue sections using
the monoclonal antibody 55k-2 (Dako, Glostrup, Denmark)
recognising a 55-kDa protein in Western blots of HeLa, normal
rat kidney, and gerbil fibroma cell lysates (Yamashiro-Matsumura
and Matsumura, 1986). This anti-fascin antibody was also found to
immunoblot bacterially expressed human homolog singed gene
(hsn) product and a 55-kDa protein from cell lysates of peripheral
blood dendritic cells (Duh et al, 1994; Mosialos et al, 1996). After
blockage of endogenous peroxidase activity with 5% hydrogen
peroxide and heat-mediated antigen retrieval with 1mM EDTA, pH
8 (Sigma Chemical Co, St Louis, MO, USA) in a microwave oven at
750W for 12min, the sections were reacted overnight at 41C with
the primary antibody at a dilution of 2.5mgml
 1 in Tris-buffered
saline. Detection was performed using a commercially available kit
(Dako EnVision Plus-HRP, Dako), according to the manufacturer’s
instructions. Peroxidase activity was developed with 3-30-diami-
nobenzidine-copper sulphate (Sigma Chemical Co) to obtain a
brownish-black end product. Tumour proliferative fraction was
assessed by Ki-67 immunostaining and the percentage of reactive
cells was recorded as the labelling index according to previously
refined immunohistochemical method (Pelosi et al, 1996). The
specificity of all immunoreactions was double-checked by
substituting the primary antibodies with nonrelated isotypic
mouse immunoglobulins at a comparable dilution and with
normal mouse serum alone (Burry, 2000).
Two observers (GP and GP) evaluated fascin immunoreactivity
of tumour cells independently and blindly, without knowledge of
the patients’ clinical outcome or of the tumour features. Results
were expressed according to the percentage of immunoreactive
cells among at least 2000 tumour cells in consecutive unselected
histological fields. Intensity of fascin immunostaining was also
graded as low (expressed as ‘1’), if a faint to distinct granular
staining was detectable throughout the cytoplasm but less intense
than seen in the normal internal controls (endothelial and
dendritic cells), or strong (expressed as ‘2’), if it was of the same
or greater intensity than the control staining. A score was then
calculated multiplying the percentage of immunoreactive cells by
the intensity level of immunostaining. Therefore, tumours were
considered negative if staining was completely absent in the
neoplastic cells; moderately positive if the fascin score ranged from
1 to 100, and strongly positive if it was higher than 100.
Statistical analysis
Associations between intramural and extramural fascin expression
and clinicopathological characteristics of the tumour were assessed
by the Fisher’s exact test for categorical variables and with the
Mantel–Haenszel w
2 test for trend for ordinal variables. Disease-
free survival was calculated from the date of surgery until the date
of either loco-regional relapse or the development of distant
metastasis. Only mortality from disease was considered for OS
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Kaplan–Meier method, whereas the comparison between the
groups was assessed by the log-rank test, considering a P-value
o0.05 as significant. The univariate and multivariate Cox
proportional hazard regression was used to assess the prognostic
significance of fascin and other clinical characteristics on survival.
As this study dealt with locally advanced and metastatic tumours
that actually have a poor prognosis, patients were censored at 6
years to emphasize the prognostic role of fascin expression as an
early predictive marker for tumour progression. All tests were two-
sided. Analyses were performed with the SAS software (Cary, NC,
USA).
RESULTS
Patients
The study encompassed 121 men (median age 66 years, range
38–84) and 107 women (median age 65, range 30–84).
Stage distribution included nine (4%) tumour patients with
stage IIIA (six men and three women), 100 (44%) with stage IIIB
(49 men and 51 women), 61 (26%) with stage IIIC (29 men and 32
women), and 58 (25%) with stage IV (37 men and 21 women).
Eighty-five patients (37%) had right colon carcinoma, 14 (6%)
transverse colon carcinoma, and 129 (57%) left colon carcinoma.
A B
CD
Figure 1 (A–D) Fascin expression in primary and metastatic lymph nodes, in conventional (A and B) and mucinous adenocarcinoma (C and D), both
showing fascin score 4100. Two other examples of adenocarcinoma (A) and lymph node metastasis (B) lacking any fascin immunoreactivity are also shown
(insets).
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Figure 2 The distribution of the fascin score along the large bowel according to the intramural (im), extramural (em), and lymph node (ln) compartments
is shown. A differential distribution was noted among the diverse intestinal tracts (Po0.001), with a prevalence of positive fascin score in the intramural
component of the right colon only as compared with the extramural or lymph node location (P¼0.025).
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sTable 1 Association between intramural and extramural fascin expression and other clinicopathological characteristics in colon cancer
Intramural fascin score Extramural fascin score Lymph nodal fascin score
Neg p100 4100 P-value Neg p100 4100 P-value Neg p100 4100 P-value
Sex
Male 43 54 24 50 41 24 51 46 23
Female 23 51 33 0.010 35 29 38 0.022 36 34 37 0.022
Age
o50 10 12 3 13 5 5 14 6 5
50–59 9 29 11 13 22 12 13 22 14
6 0 – 6 9 2 33 1 1 3 2 72 0 1 5 2 92 1 1 7
70+ 24 33 30 0.120
a 32 23 30 0.247
a 31 31 24 0.489
a
Localisation
Right 6 44 35 16 27 40 16 31 38
Transverse 4 4 6 4 5 5 4 2 8
Left 56 57 16 o0.0001 65 38 17 o0.0001 67 47 14 o0.0001
Histology
Nonmucinous 65 98 50 83 67 53 86 74 52
Mucinous 1 7 7 0.017 2 3 9 0.0042 1 6 8 0.0033
Grade
G1 5 10 1 8 5 3 9 4 3
G2 51 65 28 64 42 30 62 55 26
G3 10 30 28 o0.0001
a 13 23 29 o0.0001
a 16 21 31 o0.0001
a
pT
pT1 0 1 1 0 1 1 1 0 0
pT2 3 8 1 0 1 0 5 7 0
pT3 56 85 44 76 60 49 72 64 49
pT4 7 11 11 0.38
a 9 8 12 0.47
a 9 9 11 0.042
a
pN
N1 42 69 28 55 44 30 55 57 26
N2 24 36 29 0.12 30 26 32 0.056 32 23 34 0.032
Number of positive nodes
1 1 83 3 1 1 2 52 0 1 1 2 52 4 1 2
2 1 92 3 1 0 2 21 5 1 2 2 22 2 8
3 – 5 2 32 8 1 8 3 02 2 1 6 2 92 1 1 9
45 6 21 18 0.014
a 8 13 23 0.0018
a 11 13 21 0.0079
a
LN met
Intra LN 41 65 23 55 41 26 54 51 23
Extra LN 25 40 34 0.019 30 29 36 0.0072 33 29 37 0.0081
pM
M0 55 80 35 69 52 40 71 61 37
M1 11 25 22 0.0060 16 18 22 0.024 16 19 23 0.0080
Stage
IIIA 3 5 1 0 2 1 4 4 1
IIIB 30 50 20 44 31 23 40 42 17
IIIC 22 25 14 25 19 16 27 15 19
IV 11 25 22 0.021
a 16 18 22 0.051
a 16 19 23 0.0064
a
Ki-67 intramural
o40 18 26 15 20 20 16 19 28 12
4 0 – 5 9 2 13 1 1 2 2 81 9 1 5 2 82 2 1 4
60+ 27 46 30 0.40
a 36 30 31 0.75
a 39 29 34 0.48
a
Ki-67 extramural
o40 26 33 16 28 27 20 27 32 16
4 0 – 5 9 1 42 1 1 6 2 01 7 1 4 1 91 6 1 5
60+ 23 42 24 0.23
a 36 25 28 0.89
a 35 25 29 0.54
a
LN, lymph node. No association was found between fascin expression and centre, chemotherapeutic treatment, vascular, lymphatic, and neural invasion.
aP-value for trend using
the Mantel–Haenszel w
2 test.
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sTable 2 Univariate analysis for disease-free and overall survival
Disease free survival Overall survival (death from cancer)
Univariate analysis HR (95% CI) P-value HR (95% CI) P-value
Fascin intramural
Negative 1.00 1.00
p100 1.38 (0.93–2.05) 0.11 1.69 (1.11–2.59) 0.015
4100 1.64 (1.08–2.48) 0.020 2.01 (1.25–3.23) 0.004
Fascin intramural
Absent 1.00 1.00
Present 1.48 (1.03–2.12) 0.032 1.79 (1.20–2.68) 0.004
Fascin extramural
Negative 1.00 1.00
p100 1.31 (0.89–1.95) 0.15 1.50 (1.00–2.26) 0.057
100+ 1.53 (1.05–2.23) 0.028 1.71 (1.13–2.60) 0.012
Fascin extramural
Absent 1.00 1.00
Present 1.42 (1.02–1.97) 0.037 1.59 (1.11–2.28) 0.011
Fascin LN
Negative 1.00 1.00
p100 1.69 (1.16–2.45) 0.0058 2.04 (1.37–3.05) 0.0005
100+ 1.81 (1.20–2.71) 0.0045 1.87 (1.20–2.90) 0.0056
Fascin LN
Absent 1.00 1.00
Present 1.74 (1.24–2.43) 0.0013 1.97 (1.36–2.84) 0.0003
Localization
Left 1.00 1.00
Right-transverse 1.42 (1.04–1.95) 0.029 1.44 (1.03–2.01) 0.033
Histology
Nonmucinous 1.00 1.00
Mucinous 1.66 (0.94–2.94) 0.083 2.11 (1.19–3.75) 0.011
Grade
G1 1.00 1.00
G2 2.05 (0.96–4.42) 0.083 2.44 (0.97–6.01) 0.052
G3 2.43 (1.10–5.37) 0.029 2.96 (1.17–7.49) 0.022
PT
pT1–2 1.00 1.00
pT3–4 4.01 (1.48–10.8) 0.0062 2.93 (1.08–7.92) 0.034
PN
N1 1.00 1.00
N2 1.74 (1.27–2.39) 0.0006 1.56 (1.11–2.19) 0.0096
Number of positive nodes
1 1.00 1.00
2–5 1.65 (1.10–2.45) 0.015 1.59 (1.03–2.46) 0.035
45 2.91 (1.82–4.63) o0.00001 3.30 (2.03–5.37) o0.0001
LN met
Intra LN 1.00 1.00
Extra LN 1.79 (1.31–2.45) 0.0003 1.79 (1.28–2.50) 0.0007
PM
M0 1.00 1.00
M1 3.67 (2.62–5.15) o0.0001 5.93 (4.13–8.52) o0.0001
Stage
IIIA 0.30 (0.07–1.12 0.091 0.43 (0.11–1.77) 0.24
IIIB 1.00 1.00
IIIC 1.75 (1.17–2.63) 0.0065 1.62 (1.04–2.52) 0.033
IV 4.31 (2.94–6.32) o0.0001 6.92 (4.56–10.5) o0.0001
Venous invasion
Absent 1.00 1.00
Present 1.64 (1.20–2.25) 0.0020 1.65 (1.18–2.31) 0.0035!
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sTwenty patients (9%) experienced local recurrences and 134 (59%)
distant metastases, classified as hepatic (80 patients) abdominal
extra-hepatic (22 patients), and extra-abdominal (32 patients).
Sixteen (7%) of the adenocarcinomas were grade 1, 144 (63%)
grade 2, and 68 (30%) grade 3, with 213 (93%) of them being
typical adenocarcinoma, 13 (6%) mucinous and two (1%) signet
ring cell adenocarcinoma. Intramural venous invasion was
detected in 51 (22%) cases, extramural venous invasion in 69
(30%), lymphatic vessel invasion in 21 (9%), and perineural
invasion in 29 (13%). The distribution of these morphological
features was independent of the tumour anatomical location,
except for the tumour grade and the presence of intramural venous
invasion, with a net prevalence of high-grade tumours and
intramural vascular invasion in the right colon as compared with
the left (Po0.001). The survival curves of patients treated in the
two participating centres were not statistically different.
Immunohistochemical data
The normal colonic epithelium consistently lacked any fascin
immunoreactivity, which was instead encountered in the under-
lying lamina propria and tumour stroma, with the endothelial and
fibroblastic cells showing a consistent and strong immunoreacti-
vity for fascin.
Representative examples of fascin immunoreactivity are de-
picted in Figure 1, and its distribution along the large bowel
according to intramural, extramural, and lymph node location is
reported in Figure 2. A positive fascin score was detected in the
intramural component of 162 (71%) specimens (intramural
fascin), in the extramural component of 132 (58%) (extramural
fascin), and in metastatic lymph nodes of 141 (62%) patients.
Thirty-five tumours showed a positive fascin score in the
intramural but not in the extramural component; the opposite was
seen in only four tumours.
Among the 162 tumours positives in the intramural component,
130 had positive lymph node metastasis (80%) and among the 132
tumours positives in the extramural component 116 had positive
lymph node metastasis (88%).
Striking differences in the prevalence of fascin immunoreactivity
between right- and left-sided colon segments were found (Figure 2
and Table 1).
An intratumoural, extratumoural, and lymph node fascin score
4100 was significantly associated with the female sex, tumour
location in the right or transverse colon, more advanced tumour
stage, pN class, the pattern of lymph node involvement (with a
higher level of immunoreactivity in lymph nodes showing
extracapsular extension), higher tumour grade, mucinous histo-
type, and the occurrence of metastasis and of a heavy peritumoural
lymphoid infiltrate (Table 1). No correlations were found with
the other variables, including tumour proliferative fraction,
chemotherapeutic regimens (data not shown), and site of
metastasis.
Regarding survival, traditional prognostic variables such as the
pT, pN, tumour grade, and vascular invasion correlated well with
the patients’ life expectation (Table 2), with tumour stage according
to the TNM system being a strong predictor of survival (Figure 3). A
correlation with poorer clinical outcome was also noted for
mucinous differentiation and right tumour location (Table 2).
A positive fascin score (independent of its threshold) at any site
was significantly associated with both a shorter OS and DFS
(Figure 4A and B), even for patients with stage IV disease
(Figure 4B, bottom). In the multivariate analysis, fascin emerged as
an independent prognostic factor for both OS and DFS, together
with stage and a mucinous-signet ring histotype (Table 3).
Table 2 (Continued)
Disease free survival Overall survival (death from cancer)
Univariate analysis HR (95% CI) P-value HR (95% CI) P-value
Intramural
Absent 1.00 1.00
Present 1.34 (0.93–1.93) 0.12 1.56 (1.07–2.29) 0.022
Extramural
Absent 1.00 1.00
Present 1.74 (1.25–2.42) 0.0010 1.63 (1.14–2.32) 0.0069
Ki-67 intramural
a
o40 1.00 1.00
40–59 0.84 (0.56–1.26) 0.39 0.72 (0.47–1.10) 0.13
60+ 0.75 (0.51–1.11) 0.15 0.60 (0.40–0.91) 0.015
Ki-67 extramural
a
o40 1.00 1.00
40–59 0.89 (0.58–1.35) 0.57 0.73 (0.47–1.13) 0.16
60+ 0.79 (0.55–1.14) 0.20 0.66 (0.45–0.98) 0.039
CI, confidence interval; HR, hazards ratio; LN, lymph node. No association was found between survival and center, sex, age, lymphatic invasion, neural invasion, tumour border,
peritumoral inflammation, and adjuvant treatment.
aThese variables were associated with better survival.
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Figure 3 Overall survival analysis according to tumour stage in 228
colon adenocarcinoma patients.
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sDISCUSSION
In this study, we investigated a large series of colorectal
carcinomas for fascin immunoreactivity. The main results are that
fascin is upregulated in most colonic carcinomas, correlating with
a higher tumour grade, right tumour location and tumour stage,
and that fascin immunoreactivity is an independent predictor of
reduced OS and DFS in patients with advanced tumour stage.
A growing body of literature reports that fascin is expressed in
many types of transformed epithelial cell lines and in several solid
neoplasms (Grothey et al, 2000; Hu et al, 2000; Goncharuk et al,
2002; Jawhari et al, 2003; Pelosi et al, 2003a,b; Hashimoto et al,
2004, 2005a, 2006; Tong et al, 2005; Xie et al, 2005; Yoder
et al, 2005; Choi et al, 2006; Zhang et al, 2006) where it correlates
with tumour stage (Hashimoto et al, 2004, 2005a; Yoder et al,
2005; Choi et al, 2006) and grade (Pelosi et al, 2003b; Hashimoto
et al, 2004; Yoder et al, 2005), pT class (Hashimoto et al, 2004,
2005a), lymph node involvement (Hashimoto et al, 2004,
2005a; Choi et al, 2006; Zhang et al, 2006), recurrence (Hashimoto
et al, 2004), and both OS (Hashimoto et al, 2004, 2005a, 2006;
Yoder et al, 2005) and DFS (Pelosi et al, 2003b; Yoder et al, 2005).
The close association we found between fascin immunoreactivity
and tumour stage, tumour grade, the number and type of lymph
node involvement, and distant metastasis indicates the major role
of fascin in the progression of colonic adenocarcinoma. In our
study, fascin seems to play a different role in the progression of
right- and tranverse-sided neoplasms (as recently evidenciated)
(Hashimoto et al, 2006) and of mucinous variants of colonic
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Figure 4 (A) Disease-free and OS analysis of 228 colon adenocarcinoma patients according to intramural, extramural, and lymph node fascin expression.
(B) Overall survival of patients with stage III (top) and IV (bottom) colon adenocarcinoma according to intramural, extramural, and lymph node fascin
expression.
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sadenocarcinomas as compared with the other types of colonic
cancers (Table 2). Pelosi et al (2003b) also noted a differential
distribution of fascin immunoreactivity in mucinous and non-
mucinous bronchioloalveolar carcinomas of the lung and fascin
transfection in colonic carcinoma cell lines increased the levels
of neutral mucin (Jawhari et al, 2003). Although the clinical
implications of colorectal mucinous carcinoma are still contro-
versial, a consensus conference on colorectal carcinomas stated
that mucinous and signet ring carcinomas, when evaluated jointly,
have a poorer prognosis than intestinal-type adenocarcinomas
(Compton et al, 2000).
Although the association of fascin expression with lymph node
involvement has already been documented for other gastrointest-
inal cancers such as oesophageal and gastric carcinomas
(Hashimoto et al, 2004, 2005a) and also for pulmonary neoplasms
(Pelosi et al, 2003a; Choi et al, 2006), we have shown that fascin
immunoreactivity in colonic adenocarcinomas is also related to the
patterns of lymph node involvement (intra- vs extra-lymph nodal
colonisation). As fascin immunoreactivity is also associated with
the number of metastatic lymph nodes and the occurrence of
distant metastases, we hypothesise that this molecule is very likely
involved in the metastatic process of colonic adenocarcinoma
cells via its motility-inducing properties. This is further sustained
by the observation that patients with lymph node metastases
immunoreactive for fascin experienced a more aggressive clinical
course than patients with negative lymph node metastases
(Figure 4A). This significance was kept stratifying the prognostic
impact of fascin according to tumour stages III and IV (Figure 4B).
Thus, fascin expression in primary and metastatic tumours could
unveil the different clinical aggressiveness of tumours that are
otherwise classified in the same risk category.
Fascin immunoreactivity was not associated with the tumour
proliferation fraction as assessed by the Ki-67-labelling index, at
variance with previous studies of lung and stomach cancers and
also of colonic cell cultures (Jawhari et al, 2003; Pelosi et al, 2003b;
Hashimoto et al, 2004). In a recent work on CRC, similar to the
current one, comparing fascin expression with Ki-67 immuno-
staining, a lack of direct association between the two markers was
noted, indicating that the fascin upregulation do not correlate
positively with cell proliferation (Hashimoto et al, 2006).
However, the prognostic role of the Ki-67-labelling index in
colorectal carcinoma is still highly controversial and probably
different from other solid neoplasms. In fact, recent observations
document that a high Ki-67-labelling index is associated with
better OS (Allegra et al, 2003) in both treated and untreated
patients (Garrity et al, 2004), as reported in the current series
(Table 2).
Fascin immunoreactivity was associated with a shorter OS and
DFS, independent of tumour stage, which is the most important
prognostic factor in this tumour type (Compton and Greene,
2004). In the multivariate analysis, similar results were also
obtained for other tumour types, such as pulmonary (Pelosi et al,
2003a), oesophageal (Hashimoto et al, 2005a), breast (Yoder et al,
2005) carcinomas and more recently CRC (Hashimoto et al, 2006).
Our findings confirming that fascin is a negative prognostic factor
for advanced colonic adenocarcinoma encourage clinical transla-
tion, especially when considering that the current substaging
of colorectal cancer according to the latest TNM classification
emphasizes the prognostic heterogeneity of patients within the
same tumour stage group. The different prognostic implications of
lymph node metastases according to the amount of fascin could
well be incorporated in new staging proposals. Finally, the
identification of patients with a reduced life expectation according
to the degree of fascin expressed by their respective tumours also
justifies the potential use of novel targeted therapies, as recently
proposed for other malignant epithelial neoplasms (Hashimoto
et al, 2005b, 2006).
Additional studies are needed to investigate the role of fascin in
right-sided colonic cancer and in mucinous differentiation.
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